Senti Biosciences Holdings, Inc. — Form 8-K Summary
Business context and reporting period
The 8-K, filed October 26, 2026, reports transactions completed October 21, 2026. In the merger, Senti Merger Sub merged into Senti Holdings, Inc. (Midco), which became a wholly owned subsidiary of ST NewCo Limited, an entity controlled by Celadon Partners. The filing does not provide a financial reporting period or quarterly operating results.
Key financial and transaction metrics
- Contingent value rights (CVRs): Eligible equityholders are to receive one CVR per common share held on a record date to be fixed after closing. CVRs may provide pro rata cash payments, capped at $60 million in aggregate: $10 million upon FDA acceptance (or passage of the specified review period without rejection) of a BLA for SENTI-202; $20 million upon FDA approval; and $30 million if cumulative worldwide net sales exceed $200 million. Milestones must occur by the seventh anniversary of closing.
- Equity financing: The Company issued 7,309,941 common shares to an investor affiliated with Celadon for $0.342 per share, generating approximately $2.5 million.
- Convertible notes: $16.0 million aggregate principal amount of Midco senior secured convertible notes was outstanding at closing. Holders were notified that all notes must be exchanged for Company common shares on October 28, 2026, at an adjusted exchange price of $0.342 per share. Upon exchange, specified guarantees and security interests will terminate.
- Other financials: This 8-K does not provide revenue, profit, cash flow, margins, or liquidity figures. Unaudited pro forma financial information is referenced as Exhibit 99.1, but its figures are not included in the supplied filing text.
Material changes and agreements
- Opco assigned the Company certain patents, related rights, external research agreements, and know-how relating to the Rett Syndrome and TIL programs. The Company assumes specified obligations under those agreements arising on or after the effective date; the filing states no payment is owed to Opco under the assignment.
- Opco will provide transitional corporate, administrative, financial, IT, operational, and R&D support under a consulting agreement with an initial 12-month term and a possible 12-month extension. Fees apply; the Company may terminate individual services with prior notice.
- The Company agreed to file resale registration statements for the investor’s newly issued shares within 30 days after closing and to use the stated efforts to obtain and maintain effectiveness.
- Outstanding stock options and RSUs vested immediately before the merger’s effective time, subject to their applicable terms. Eligible options, RSUs, and warrants may entitle holders to CVRs in connection with exercise or settlement.
Outlook, risks, and unusual items
- CVR payments are speculative, not guaranteed, and depend on product development, regulatory outcomes, and commercial sales. CVRs are not equity interests, have no voting or dividend rights, and are generally nontransferable.
- Celadon controls Parent and is affiliated with the Company’s largest stockholder, a noteholder, and the equity investor. The Company says an independent special committee unanimously found the merger advisable, fair, and in stockholders’ best interests; the Board approved it, with a Celadon-designated member absent from the vote.
- The filing provides no operating guidance or forecast. It identifies transaction-dependent milestone payments and ongoing consulting fees but does not state their accounting treatment or the Company’s post-transaction cash position.
Investor facts to verify
- The CVR record date, distribution mechanics, and each holder’s eligibility, including treatment of options, RSUs, and warrants.
- Whether the October 28 note exchange was completed, the number of shares issued, and the resulting dilution and capital structure.
- The financial statements and assumptions in Exhibit 99.1 and the resulting post-transaction liquidity and operating outlook.
- Filing and effectiveness of the resale registration statement, and the fees and remaining obligations under the consulting and assigned research agreements.
- Development, FDA review, approval, and commercial progress for SENTI-202 that could trigger CVR payments.